Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - Nasdaq

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS Nasdaq Novartis International AG / Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content ... and more »

Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS - Nasdaq
Read More